Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Iperboreal Pharma Srl
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, China, Denmark, Germany, Italy, Spain, Sweden, United Kingdom
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Colorectal Cancer|Diabetic Foot|Kidney Diseases|Kidney Failure, Chronic|Prostate Cancer|Soft Tissue Infections
Phase 2: Type 2 Diabetes
Phase 1: Angina Pectoris|Common Cold|Coronary Disease|Healthy Volunteers|Myocardial Infarction|Nasopharyngitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IP-001-18 | P3 |
Recruiting |
Kidney Diseases |
2025-12-31 |
|
| ELIXIR | P3 |
Recruiting |
Kidney Failure, Chronic |
2024-12-01 |
49% |
| ELIXIR | P3 |
Active, not recruiting |
Kidney Diseases |
2023-11-06 |
|
| 2-DG-01 | P1 |
Completed |
Nasopharyngitis|Common Cold |
2023-08-01 |
21% |